Strategic divestiture Recent asset sale to Athira Pharma with upfront and potential milestone/royalty structure suggests a potential interest in strategic partnerships or licensing deals. Sales opportunities could focus on identifying alternative buyers or negotiating co-development arrangements for ESR1-mutated cancer programs.

Collaborative potential Integration with Regor Pharmaceuticals to merge clinical drug development with computational discovery signals openness to external collaboration. Opportunities exist to propose joint development, data-sharing agreements, or access to Regor’s discovery tools for accelerating ESR1-mutated cancer programs.

Clinical traction ELAINE trials and case reports demonstrating Complete Remission in metastatic breast cancer provide evidence of therapeutic potential. Use these successes to engage both academic centers and oncology networks for investigator-initiated trials, research collaborations, and potential expansion of trial sites.

Diagnostic alignment Past partnerships with Guardant Health for liquid biopsy screening indicate a pathway for precision enrollment. A sales focus could target companion diagnostic collaborations, CDx integration, and payer discussions tied to ESR1 mutation screening and patient stratification.

Funding signals Multiple funding rounds and notable investor activity (Series A3, private placement) imply appetite for strategic relationships and co-development funding. Target discussions around sponsored studies, milestone-based partnerships, and potential co-investment opportunities to de-risk late-stage development.